Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 4 1Phase 2 1Phase 1/2 1

Status

Recruiting 5Active not recruiting 4Not yet recruiting 2Withdrawn 1Unknown 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5

Conditions

Multiple Myeloma 5Recurrence 3Neoplasms 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Carcinoma, Non-Small-Cell Lung 2Burkitt Lymphoma 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Pleural Effusion, Malignant 1Ovarian Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Cytokine Release Syndrome 1Craniopharyngioma 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma 1Advanced Liver Cancers 1

Interventions

Dexamethasone 87daratumumab 49Lenalidomide 49pomalidomide 33Bortezomib 32Cyclophosphamide 31carfilzomib 25Calcium Dobesilate 21talquetamab 19fludarabine 18isatuximab 16iberdomide 16Magnetic Resonance Spectroscopy 16Specimen Handling 15Biopsy 14selinexor 12Melphalan 11belantamab mafodotin 10dexamethasone acetate 9dexamethasone 21-phosphate 8elotuzumab 7auricularum 7venetoclax 6tocilizumab 5fludarabine phosphate 5X-Rays 5Blood Specimen Collection 5ruxolitinib 4Methylprednisolone 4Injections 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Multiple Myeloma × tocilizumab × Clear all
NCT06934044 2026-05-11

A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma

Hoffmann-La Roche

Phase 1 Recruiting
20 enrolled
Plasma cell

Multiple Myeloma

NCT05583617 2026-05-04

PLYCOM

Hoffmann-La Roche

Phase 1/2 Recruiting
200 enrolled
Plasma cell

Multiple Myeloma

NCT05927571 2026-05-04

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Genentech, Inc.

Phase 1 Recruiting
120 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT05972135 2026-04-22

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

SCRI Development Innovations, LLC

Phase 2 Recruiting
100 enrolled
Plasma cell

Cytokine Release Syndrome, Multiple Myeloma

NCT06251076 2025-12-10

Plan Development for Giving Teclistamab in the Outpatient Setting

University Health Network, Toronto

Phase 4 Recruiting
15 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡